RP Management, LLC is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $2.1 billion in regulatory assets under management. Its private funds, of all types, hold $1.2 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated -26.3% 2025 YTD through Mar 31 (S&P 500: -4.5%), based on 13F filings. Over a longer period they returned an estimated -23.9% from Q3 2024 to Q1 2025, compared with +2.8% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $2.1 billionForm ADV Item 5.F
- Gross assets of private funds
- $1.2 billionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- 2Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 161569
- Latest Form ADV
- 03/31/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q1 2025 | -26.3% | -4.5% |
| Q4 2024 | -18.9% | +2.1% |
| Q3 2024 | +27.4% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Largest disclosed holdings
- Biohaven LTD$70.6 million
- Cytokinetics Inc$39.4 million
- Biocryst Pharmaceuticals Inc$28.8 million
- 92765f108$74
As of 2025-03-31, from 13F filing by RP Management, LLC.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures